



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): BOYLE, et al.

Serial No.: 09/613,591 Group Art Unit No.: 1647
Filed: JULY 10, 2000 Examiner: R. Deberry
For: COMBINATION THERAPY FOR CONDITIONS
LEADING TO BONE LOSS
Docket No.: A-378CIP5 REC

RECEIVED

OCT 08 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action dated June 4, 2002, Paper No. 25, the Applicants request that the following amendments be made to the above application:

SPECIFICATION

At page 5, lines 14-36, replace with the following paragraph:

Figure 1. A. FASTA analysis of novel EST LORF. Shown is the deduced FRI-1 amino acid sequence aligned to the human TNFR-II sequence (SEQ ID NO: 169 and SEQ ID NO: 138). B. Profile analysis of the novel EST LORF shown is the deduced FRI-1 amino acid sequence aligned to the TNFR-profile (SEQ ID NO: 170 and SEQ ID NO: 178). C. Structural view of TNFR superfamily indicating region which is homologous to the novel FRI-1.

Figure 2. Structure and sequence of full length rat OPG gene, a novel member of the TNFR superfamily. A. Map of pMOB-B1.1 insert. Box indicates position of LORF within the cDNA sequence (bold line). Black box indicates signal peptide, and gray ellipses indicate position of cysteine-rich repeat sequences. B, C. Nucleic acid and protein sequence of the Rat OPG cDNA. The predicted signal peptide is underlined, and potential sites of N-linked glycosylation are indicated in bold, underlined letters (SEQ ID NO: 120 and 121). D, E. Pileup sequence comparison (Wisconsin GCG Package, Version 8.1) of OPG with other members of the TNFR superfamily, fas (SEQ ID NO:128); tnfr1 (SEQ ID NO: 129); sfu-t2 (SEQ ID NO:130); tnfr2 (SEQ ID NO:131); cd40 (SEQ ID NO:132); osteo (SEQ ID NO:133); ngfr (SEQ ID NO:134); ox40 (SEQ ID NO:135); 41bb (SEQ ID NO:136)..

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number:

EL360691385US

Date of
Deposit

October 2, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231.

I hereby certify that this paper or fee is being deposited with the United States Postal Service above and is addressed to Commissioner of Patents and Trademarks, Washington, D.C.

Express Mail Post Office to Addressee* service under 37 C.F.R. 1.10 on the date indicated
11. 
Signature/